このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

ABI-008 Trial in Patients With Metastatic Breast Cancer

2019年11月13日 更新者:Celgene

A Phase I/II Trial of ABI-008 (Nab-docetaxel) in Patients With Metastatic Breast Cancer

To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of ABI-008 giver every 3 weeks; to characterize the toxicities of ABI-008; and to determine the pharmacokinetic parameters for ABI-008 when given on an every-3-week schedule to patients with metastatic breast cancer.

調査の概要

状態

終了しました

研究の種類

介入

入学 (予想される)

85

段階

  • フェーズ2
  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Texas
      • Houston、Texas、アメリカ、77030
        • University of Texas M.D. Anderson Cancer Center

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

Phase I Study

Each subject must meet the following criteria to be enrolled in this study.

  1. Pathologically confirmed adenocarcinoma of the breast with metastasis.
  2. No more than 2 prior chemotherapy regimen for metastatic breast cancer. Patient should have received anthracycline and may have received a taxane but not within 6 months for registration on the study.
  3. Patient may have measurable or evaluable disease.
  4. Patient may have non-measurable bone only disease.
  5. At least 4 weeks since prior cytotoxic chemotherapy. Patients should have recovered from all acute effects of such therapy.
  6. At least 4 weeks since radiotherapy, with full recovery.
  7. At least 4 weeks since recovery from major surgery, with full recovery.
  8. ECOG performance status 0-2.
  9. Age ≥18 years.
  10. Patient must have the following blood counts at Baseline:

    • WBC > 3.0 x 109 cells/L;
    • ANC ≥ 1.5 x 109 cells/L;
    • Platelets ≥ 100 x 109 cells/L;
    • Hgb ≥ 9 grams/dL.
  11. Patient has the following blood chemistry levels at Baseline:

    • AST (SGOT), ALT (SGPT) ≤ 1.5x upper limit of normal range (ULN);
    • Total Bilirubin < ULN;
    • Alkaline phosphatase ≤ 2.5x ULN (unless bone metastasis is present in the absence of liver metastasis);
    • Creatinine ≤ 1.5 mg/dL.
  12. Peripheral neuropathy Grade 0 or stable Grade 1, by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0.
  13. If female of childbearing potential, serum pregnancy test is negative (within 72 hours of the first dose of study drug).
  14. If fertile, the patient agrees to use an effective method to avoid pregnancy for the duration of the study.
  15. Life expectancy should be ≥ 3 months.
  16. Informed consent document has been obtained stating that the patient understands the investigational nature of the proposed treatment.
  17. If obese, a patient must be treated with doses calculated using his/her actual body surface area (BSA) (the physician must be comfortable treating at the full BSA dose regardless of BSA).

Phase II Study

  1. Pathologically confirmed adenocarcinoma of the breast with metastasis.
  2. Patients should have not received prior chemotherapy for their metastatic disease. If a taxane is used as adjuvant or neoadjuvant therapy, at least 12 months should have elapsed from the date of the last dose.
  3. Patient must have at least one measurable metastatic lesion.
  4. At least 4 weeks since prior cytotoxic chemotherapy. Patients should have recovered from all acute effects of such therapy.
  5. At least 4 weeks since radiotherapy, with full recovery.
  6. At least 4 weeks since major surgery, with full recovery.
  7. ECOG performance status 0-2.
  8. Age ≥18 years.
  9. Patient must have the following blood counts at Baseline:

    • WBC > 3.0 x 109 cells/L;
    • ANC ≥ 1.5 x 109 cells/L;
    • Platelets ≥ 100 x 109 cells/L;
    • Hgb ≥ 9 grams/dL.
  10. Patient has the following blood chemistry levels at Baseline:

    • AST (SGOT), ALT (SGPT) ≤ 1.5x upper limit of normal range (ULN);
    • Total Bilirubin < ULN;
    • Alkaline phosphatase ≤ 2.5x ULN (unless bone metastasis is present in the absence of liver metastasis);
    • Creatinine ≤ 1.5 mg/dL.
  11. Peripheral neuropathy Grade 0 or stable Grade 1, by NCI CTCAE v3.0.
  12. If female of childbearing potential, serum pregnancy test is negative (within 72 hours of the first dose of study drug).
  13. If fertile, the patient agrees to use an effective method to avoid pregnancy for the duration of the study.
  14. Life expectancy should be ≥ 3 months.
  15. Informed consent document has been obtained stating that the patient understands the investigational nature of the proposed treatment.

Exclusion Criteria:

Phase I Study

Subjects who meet any of the following criteria will be excluded from the study.

  1. Concurrent therapy (chemotherapy, hormonal therapy, kinase inhibitors, immunotherapy, etc) for breast cancer. Bisphosphonates are allowed.
  2. Parenchymal brain metastases, unless documented to be clinically and radiographically stable for at least 6 months after treatment.
  3. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  4. Patients with significant cardiovascular disease including congestive heart failure (New York Heart Association Class III or IV), active angina pectoris or recent myocardial infarction (within the last 6 months).
  5. History of other malignancy within the last 5 years which could affect the diagnosis or assessment of breast cancer excluding non-melanomatous skin cancer and cervical carcinoma in situ.
  6. Patients who have received an investigational drug within the previous 4 weeks.
  7. Patient is currently enrolled in any other clinical study in which investigational procedures are performed or investigational therapies are administered. A patient may not enroll in such clinical trials while participating in this study.
  8. Pregnant or nursing women.
  9. Patients with history of allergic reactions attributed to solvent-based docetaxel(Taxotere).
  10. ECOG performance status 3-4.
  11. Because patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy, HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with docetaxel. Appropriate studies will be undertaken in patients receiving combination anti-retroviral therapy when indicated.

Phase II Study

Subjects who meet any of the following criteria will be excluded from the study.

  1. Prior neo-adjuvant or adjuvant chemotherapy is allowed. If a taxane was part of the adjuvant regimen, at least 12 months should have transpired since completion of taxane regimen.
  2. Concurrent therapy (chemotherapy, hormonal therapy, kinase inhibitors, immunotherapy, etc) for breast cancer.
  3. Parenchymal brain metastases, unless documented to be clinically and radiographically stable for at least 6 months after treatment.
  4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  5. Patients with significant cardiovascular disease including congestive heart failure (New York Heart Association Class III or IV), active angina pectoris or recent myocardial infarction (within the last 6 months).
  6. History of other malignancy within the last 5 years which could affect the diagnosis or assessment of breast cancer excluding non-melanomatous skin cancer and cervical carcinoma in situ.
  7. Patients who have received an investigational drug within the previous 4weeks.
  8. Patient is currently enrolled in any other clinical study in which investigational procedures are performed or investigational therapies are administered.
  9. Pregnant or nursing women.
  10. Patients with history of allergic reactions attributed to solvent-based docetaxel(Taxotere).
  11. ECOG performance status 3-4.
  12. Because patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy, HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with docetaxel.
  13. Patients with tumor overexpression of HER2/neu.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

この研究は何を測定していますか?

主要な結果の測定

結果測定
時間枠
To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of ABI-008 giver every three weeks.
時間枠:End of Study (EOS) and Follow Up
End of Study (EOS) and Follow Up

二次結果の測定

結果測定
時間枠
To evaluate the safety and tolerability of ABI-008 in the metastatic breast cancer patient population; and to determine the pharmacokinetic parameters for ABI-008 when given on an every-3-week schedule.
時間枠:End of Study (EOS) and Follow Up
End of Study (EOS) and Follow Up

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Nuhad Ibrahim, MD、M.D. Anderson Cancer Center

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2007年11月1日

一次修了 (実際)

2008年12月1日

研究の完了 (実際)

2008年12月1日

試験登録日

最初に提出

2007年9月14日

QC基準を満たした最初の提出物

2007年9月14日

最初の投稿 (見積もり)

2007年9月18日

学習記録の更新

投稿された最後の更新 (実際)

2019年11月14日

QC基準を満たした最後の更新が送信されました

2019年11月13日

最終確認日

2019年11月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する